THU345 SGLT2 Inhibitors Reduce Mortality In Patients With Acute Myocardial Infarction And Percutaneous Coronary Intervention: A Systematic Review And Meta-analysis

Disclosure: S.G. Ribeiro: None. P.E. Carvalho: None. A.B. Neto: None. N. Felix: None. L. Teixeira: None. M.M. Gauza: None. M.S. Guisso: None. C.C. Jorge: None. P.M. Camara: None. J.C. Neto: None. A.R. Amaral: None. J.D. Sa: None. Background: The effects of sodium-glucose cotransporter 2 inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Goncalves Ribeiro, Sandro Augusto, Carvalho, Pedro E P, do Amaral Neto, Augusto Barreto, Felix, Nicole, Teixeira, Larissa, Gauza, Mateus Miranda, Schramm Guisso, Maria Eduarda, Campelo Jorge, Carlos Alberto, da Camara, Pedro Matos, Costa Neto, Jose Amir, do Amaral, Adilaine Rosa, de Sa, Joao Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Diabetes And Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554995/
http://dx.doi.org/10.1210/jendso/bvad114.778
Descripción
Sumario:Disclosure: S.G. Ribeiro: None. P.E. Carvalho: None. A.B. Neto: None. N. Felix: None. L. Teixeira: None. M.M. Gauza: None. M.S. Guisso: None. C.C. Jorge: None. P.M. Camara: None. J.C. Neto: None. A.R. Amaral: None. J.D. Sa: None. Background: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the prognosis of patients with acute myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI) is not well established. Objectives: We performed a systematic review and meta-analysis to compare cardiovascular endpoints in patients undergoing PCI after acute MI treated with versus without SGLT2i. Methods: Medline, Cochrane, and Embase were systematically searched for randomized and non-randomized controlled trials that reported cardiovascular outcomes after SGLT2i initiation following PCI in patients with acute MI. Odds ratio (OR) with 95% confidence intervals (CI) were pooled with a random-effects model. Risk of bias assessment was performed as outlined by Cochrane recommendations. Results: There were 6 included studies, with 2,147 patients with acute MI and PCI, of whom 597 (27.8%) received SGLT2i therapy; 1,085 (50.5%) had diabetes mellitus. Two studies were randomized, whereas 4 studies were non-randomized cohorts. Treatment with SGLT2i reduced all-cause mortality (OR 0.49; 95% CI 0.26-0.95; p=0.03; I(2)=0%) and severe arrhythmia (OR 0.31; 95% CI 0.12-0.79; p=0.01; I(2)=0%) compared with no SGLT2i therapy. In contrast, there was no difference between groups in the incidence of myocardial infarction (OR 0.47; 95% CI 20-1.10; p=0.09; I(2)=40%) and repeat revascularizations (OR 0.86; 95% CI 0.34-2.13; I(2)=61%). Conclusion: In this meta-analysis of 2,147 patients with acute MI undergoing PCI, SGLT2i significantly reduced all-cause mortality and severe arrhythmia compared to no SGLT2i therapy. Presentation: Thursday, June 15, 2023

Ejemplares similares